| Literature DB >> 26915661 |
Wouter van Ballegooijen1,2,3, Heleen Riper4,5, Pim Cuijpers6,7, Patricia van Oppen8,9, Johannes H Smit10,11.
Abstract
BACKGROUND: Online questionnaires for measuring common mental health disorders such as depression and anxiety disorders are increasingly used. The psychometrics of several pen-and-paper questionnaires have been re-examined for online use and new online instruments have been developed and tested for validity as well. This study aims to review and synthesise the literature on this subject and provide a framework for future research.Entities:
Mesh:
Year: 2016 PMID: 26915661 PMCID: PMC4766750 DOI: 10.1186/s12888-016-0735-7
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Fig. 1Flow chart of included studies
Transdiagnostic online self-report instruments and the number of studies that report psychometric characteristics (between parentheses)
| Instrument | Purpose | N studies | Population / setting | Countries in which the studies were conducted | Internal consistency (alpha) | Test-retest reliability | Factor structure | Mean score difference with paper version | Convergent validity | Criterion validity (AUC) |
|---|---|---|---|---|---|---|---|---|---|---|
| Anxiety | ||||||||||
| BAI | Symptom severity | 3 | G1, P3 | SE | .88–.89 (2) | 4 factors (1) | None, lower (2) | |||
| Depression and anxiety | ||||||||||
| CIDI-SF | Diagnosis & screening | 1 | G1 | SE | (1) | |||||
| DASS | Symptom severity | 1 | G5 | US | .93–.95 (1) | (1) | (1) | |||
| HADS | Screening & symptom severity | 5 | G1, G5, P5, P7 | NZ, SE, UK | .76–.88 (5) | (1) | 3 factors (2) | None (2) | (1) | |
| SQ-48 | Screening & symptom severity | 1 | G1, P1 | NL | .84–.93 (1) | 9 factors (1) | (1) | .75–.91 (1) | ||
| WB-DAT | Screening | 1 | P8 | CA | (1) | |||||
| WSQ | Screening | 1 | G1 | NL | .65–.81 (1) | |||||
| Depression and anxiety (postpartum) | ||||||||||
| PDM | Screening | 1 | G1 | US | .84–.88 (1) | 2 factors (1) | (1) | |||
G1: General population; G2: Adult females; G3: Adult males; G4: General teenage population; G5: Student population; G6: General young adult population; G7: Veteran population; P1: Patient population; P2: Adult psychiatric outpatients; P3: Adult social phobia patients; P4: Adult GP patients; P5: Hearing impaired clinical population; P6: Deaf population; P7: Adults with chronic fatigue syndrome; P8: Participants in studies of the Centre for Addiction and Mental Health; AU: Australia; CA: Canada; DK: Denmark; ES: Spain; NL: Netherlands; NO: Norway; NZ: New Zealand; SE: Sweden; TW: Taiwan; UK: United Kingdom; US: United States; AUC: Area Under the Receiver Operating Characteristic Curve
Online self-report instruments for depression and the number of studies that report psychometric characteristics (between parentheses)
| Instrument | Purpose | N studies | Population / setting | Countries in which the studies were conducted | Internal consistency (alpha) | Test-retest reliability | Factor structure | Mean score difference with paper version | Convergent validity | Criterion validity (AUC) |
|---|---|---|---|---|---|---|---|---|---|---|
| Depression | ||||||||||
| BDI | Symptom severity | 2 | G1 | SE | .88 (1) | 3 factors (1) | Higher (1) | |||
| BDI-II | Symptom severity | 2 | G1 | SE | .87–.95 (2) | None, lower (2) | ||||
| CES-D | Screening & symptom severity | 6 | G1, G2, G4, G5 | NL, TW, US | .89–.93 (5) | 2–4 factors (2) | None (2) | (2) | .84–.90 (2) | |
| CES-D (7-item) | Symptom severity | 1 | G5 | ES | .82 (1) | 1 factors (1) | None (1) | (1) | ||
| CES-D (10-item) | Symptom severity | 1 | G1 | US | .86 (1) | |||||
| CUDOS | Screening & symptom severity | 1 | P2 | US | .93 (1) | None (1) | (1) | |||
| EDS | Screening | 1 | G1 | NL | .87 (1) | (1) | ||||
| HSCL-10 | Screening | 1 | G4 | DK + NO | .87 (1) | .79 (1) | ||||
| ISP-D | Screening | 2 | G1 | TW | (1) | (1) | ||||
| K-10 | Screening & symptom severity | 1 | G1 | NL | .90 (1) | (1) | .81 (1) | |||
| K&D mood scale | Symptom severity | 1 | G5 | US | .75–.79 (1) | (1) | (1) | |||
| MADRS-S | Symptom severity | 6 | G1, P3 | SE | .73–.90 (5) | 3 factors (1) | None (4) | |||
| MDI | Screening & symptoms severity | 1 | G4 | NL | .82 (1) | (1) | .89 (1) | |||
| MDRS-22 | Screening & symptom severity | 1 | G3 | AU | 6 factors (1) | (1) | ||||
| Moodscope | Symptom severity | 1 | P4 | UK | (1) | |||||
| PDI MDD | Diagnosis & screening | 1 | P1 | US | (1) | (1) | ||||
| PHQ-9 BSL | Symptom severity | 1 | P6 | UK | .81 (1) | 2 factors (1) | (1) | |||
| Single item depr. scale | Screening & symptom severity | 1 | G1 | NL | (1) | .71 (1) | ||||
| USDI | Symptom severity | 1 | G5 | AU | .95 (1) | 3 factors (1) | (1) | |||
| ZDS | Symptom severity | 1 | G5 | UK | .89 (1) | (1) | ||||
| Postpartum depression | ||||||||||
| EPDS | Screening, symptom severity | 1 | G2 | unclear | .90 (1) | 3 factors (1) | (1) | |||
| PDSS | Screening & symptom severity | 1 | G2 | US | .97 (1) | (1) | ||||
G1: General population; G2: Adult females; G3: Adult males; G4: General teenage population; G5: Student population; G6: General young adult population; G7: Veteran population; P1: Patient population; P2: Adult psychiatric outpatients; P3: Adult social phobia patients; P4: Adult GP patients; P5: Hearing impaired clinical population; P6: Deaf population; P7: Adults with chronic fatigue syndrome; P8: Participants in studies of the Centre for Addiction and Mental Health; AU: Australia; CA: Canada; DK: Denmark; ES: Spain; NL: Netherlands; NO: Norway; NZ: New Zealand; SE: Sweden; TW: Taiwan; UK: United Kingdom; US: United States; AUC: Area Under the Receiver Operating Characteristic Curve
Online self-report instruments for GAD, panic disorder and agoraphobia, social phobia, specific phobia, OCD and PTSD, and the number of studies that report psychometric characteristics (between parentheses)
| Instrument | Purpose | N studies | Population/setting | Countries in which the studies were conducted | Internal consistency (alpha) | Test-retest reliability | Factor structure | Mean score difference with paper version | Convergent validity | Criterion validity (AUC) |
|---|---|---|---|---|---|---|---|---|---|---|
| GAD | ||||||||||
| GAD-1 | Screening | 1 | G1 | NL | .78 (1) | |||||
| GAD-2 | Screening | 1 | G1 | NL | .76 (1) | |||||
| GAD-7 | Screening & symptom severity | 1 | G1 | NL | .86 (1) | 1 factor (1) | (1) | .77 (1) | ||
| GAD-7 BSL | Symptom severity | 1 | P6 | UK | .88 (1) | 1 factor (1) | (1) | |||
| PDI GAD | Diagnosis & screening | 1 | P1 | US | (1) | (1) | ||||
| Panic disorder and agoraphobia | ||||||||||
| ACQ | Symptom severity | 2 | G1 | AU, SE | .81–.84 (2) | None, lower (2) | ||||
| BSQ | Symptom severity | 2 | G1 | AU, SE | .84–.86 (2) | None, lower (2) | ||||
| CIDI-Panic subscale | Diagnosis & screening | 1 | G1 | SE | (1) | |||||
| MI | Symptom severity | 2 | G1 | AU, SE | .94–.97 (2) | None, higher (2) | ||||
| PDSS-SR item 4 | Screening | 1 | G1 | NL | .68 (1) | |||||
| PDSS-SR item 5 | Screening | 1 | G1 | NL | .61 (1) | |||||
| VS-CMD-agoraphobia | Screening | 1 | G1 | NL | .73 (1) | |||||
| Social phobia | ||||||||||
| LSAS-SR | Symptom severity | 2 | G1, P3 | SE | .93–.94 (2) | None (1) | ||||
| SIAS | Symptom severity | 3 | G5, P3 | SE, US | .86–.93 (3) | 1 factor (1) | None (2) | (2) | ||
| SPIN | Symptom severity | 1 | G1 | TW | .94 (1) | (1) | 3 factors (1) | .87 (1) | ||
| SPS | Symptom severity | 2 | G5, P3 | SE, US | .89–.93 (2) | 1 factor (1) | None (2) | (1) | ||
| Specific phobia (aviophobia) | ||||||||||
| FAS | Screening & symptom severity | 1 | G1 + G5 | US | .94–.99 (1) | .99 (1) | ||||
| OCD | ||||||||||
| C-FOCI | Screening | 1 | G4 | US | .73 (1) | |||||
| OBQ-44 | Symptom severity | 1 | G5 | US | .97 (1) | None (1) | (1) | |||
| OCI | Symptom severity | 1 | G5 | US | .94 (1) | None (1) | (1) | |||
| PI | Symptom severity | 1 | G1 | US (mainly) | 4 factors (1) | |||||
| PTSD | ||||||||||
| NSES | Diagnosis & symptom severity | 1 | G1, G7 | US | 4 factors (1) | |||||
| PCL-C | Symptom severity | 1 | G5 | US | .91 (1) | None (1) | ||||
| PSS | Screening & symptom severity | 1 | G5 | US | .92–.94 (1) | 4 factors (1) | (1) | |||
| TSS | Symptom severity | 1 | G5 | US | .95–.96 (1) | None (1) | ||||
| PTSD (peripartum) | ||||||||||
| PPQ (modified) | Screening & symptom severity | 1 | G2 | US | .90 (1) | 3 factors (1) | (1) | (1) |
G1: General population; G2: Adult females; G3: Adult males; G4: General teenage population; G5: Student population; G6: General young adult population; G7: Veteran population; P1: Patient population; P2: Adult psychiatric outpatients; P3: Adult social phobia patients; P4: Adult GP patients; P5: Hearing impaired clinical population; P6: Deaf population; P7: Adults with chronic fatigue syndrome; P8: Participants in studies of the Centre for Addiction and Mental Health; AU: Australia; CA: Canada; DK: Denmark; ES: Spain; NL: Netherlands; NO: Norway; NZ: New Zealand; SE: Sweden; TW: Taiwan; UK: United Kingdom; US: United States; AUC: Area Under the Receiver Operating Characteristic Curve
Online self-report instruments for stress, worrying, suicidal ideation and self-harm, and the number of studies that report psychometric characteristics (between parentheses)
| Instrument | Purpose | N studies | Population/setting | Countries in which the studies were conducted | Internal consistency (alpha) | Test-retest reliability | Factor structure | Mean score difference with paper version | Convergent validity | Criterion validity (AUC) |
|---|---|---|---|---|---|---|---|---|---|---|
| Stress | ||||||||||
| PSS | Symptom severity | 1 | G5 | ES | .72 (1) | 1 factor (1) | None/lower (1) | (1) | ||
| Worry | ||||||||||
| PSWQ | Symptom severity | 2 | G1, G5 | NL, US | .73–.88 (2) | (1) | 1 factor (1) | (1) | ||
| Worry (postpartum) | ||||||||||
| PWS-R | Symptom severity | 1 | G2 | US | .64–.88 (1) | 4 factors (1) | (1) | |||
| Self-harm | ||||||||||
| ISAS | Symptom severity | 1 | G6 | US + UK + CA + AU | .77–.87 (1) | 2 factors (1) | (1) | |||
| Suicidal ideation | ||||||||||
| BDI-II item 9 | Screening | 1 | G1 | SE | Lower (1) | |||||
| MADRS-S item 9 | Screening | 1 | G1 | SE | None (1) |
G1: General population; G2: Adult females; G3: Adult males; G4: General teenage population; G5: Student population; G6: General young adult population; G7: Veteran population; P1: Patient population; P2: Adult psychiatric outpatients; P3: Adult social phobia patients; P4: Adult GP patients; P5: Hearing impaired clinical population; P6: Deaf population; P7: Adults with chronic fatigue syndrome; P8: Participants in studies of the Centre for Addiction and Mental Health; AU: Australia; CA: Canada; DK: Denmark; ES: Spain; NL: Netherlands; NO: Norway; NZ: New Zealand; SE: Sweden; TW: Taiwan; UK: United Kingdom; US: United States; AUC: Area Under the Receiver Operating Characteristic Curve